Bevacizumab for Patients with Recurrent Multifocal Glioblastomas

In patients with glioblastoma, antiangiogenic therapy with bevacizumab (BEV) has been shown to improve progression-free survival (PFS), but not overall survival (OS). Especially in patients with an unusual infiltrative phenotype as seen in multifocal glioblastoma, the use of BEV therapy is still mor...

Descripción completa

Detalles Bibliográficos
Autores principales: Burger, Michael C., Breuer, Stella, Cieplik, Hans C., Harter, Patrick N., Franz, Kea, Bähr, Oliver, Steinbach, Joachim P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5713435/
https://www.ncbi.nlm.nih.gov/pubmed/29156610
http://dx.doi.org/10.3390/ijms18112469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5713435/
https://www.ncbi.nlm.nih.gov/pubmed/29156610
http://dx.doi.org/10.3390/ijms18112469

Ejemplares similares